Controlled Delivery of Paclitaxel via Stable Synthetic Protein Nanoparticles

• DOI: 10.1002/adtp.202400208
• Publication Date: 2024-06-27T10:42:18Z
• Authors: Ava Mauser; Isabel Waibel; Kaushik Banerjee; Anzar A. Mujeeb; Jingyao Gan; Sophia Lee; William Brown; Nigel Lang; Jason Gregory; Jeffery Raymond; Matthias Franzeb; Anna Schwendeman; Maria G. Castro; Joerg Lahann
• Keywords: Zeta potential

Abstract Despite decades of intense research, glioma remains a disease for which no adequate clinical treatment exists. Given the ongoing therapeutic failures conventional approaches, nanomedicine may offer alternative options because it can increase bioavailability drugs and alter their pharmacokinetics. Here, new type synthetic protein nanoparticles (SPNPs) is reported that allow effective loading controlled release potent cancer drug, paclitaxel (PTX) – drug so far has been unsuccessful in due to hydrophobicity, low solubility, associated delivery challenges. SPNPs are prepared by electrohydrodynamic (EHD) jetting dilute solutions PTX‐loaded albumin made high‐pressure homogenization. After EHD jetting, PTX possess dry diameter 165 ± 44 nm, hydrated 297 102 zeta potential −19 8 mV water. For SPNP formulation with total 9.4%, efficiency 94%, observed over two weeks (6% burst release). more (68% lethality) than free (45% lethality using 0.2% dimethyl sulfoxide). combination IR show significant survival benefit glioma‐bearing mouse models, avoid adverse liver toxicity, maintain normal brain architecture. Immunohistochemistry reveals dramatic tumor size reduction including 40% long‐term survivors without discernible signs tumor. Using flexibly engineered SPNPs, this work outlines an efficient strategy hydrophobic otherwise notoriously hard deliver.